Calliditas Therapeutics Ab logo

Calliditas Therapeutics Ab Share Price (NASDAQ: CALT)

▲

-40

(-100%)

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 20 Sep 2024

Check the interactive Calliditas Therapeutics Ab Stock chart to analyse performance

Calliditas Therapeutics Ab Key Stats

Check Calliditas Therapeutics Ab key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$40.0001
Open
$40.0
Market Capitalization
$1.1B
Today's Volume
$9.8K
Revenue TTM
$1.6B
EBITDA
$-365.4M
Earnings Per Share (EPS)
$-1.75
Profit Margin
-30.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-157.2%

Global Institutional Holdings in Calliditas Therapeutics Ab

  • Name

    Holdings %

  • Bvf Inc

    2.78%

  • Ironwood Investment Management LLC

    0.09%

  • Optiver Holding B.V.

    0.08%

  • UBS Group AG

    0.04%

  • Penderfund Capital Management Ltd

    0.02%

  • Susquehanna International Group, LLP

    0.02%

Analyst Recommendation on Calliditas Therapeutics Ab Stock

Rating
Trend

Buy

    85%Buy

    14%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Calliditas Therapeutics Ab(by analysts ranked 0 to 5 stars)

About Calliditas Therapeutics Ab

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation.
Organization
Calliditas Therapeutics Ab
Employees
222
CEO
Ms. Renee Aguiar-Lucander
Industry
Health Technology

Important FAQs about investing in CALT Stock from India :

What is Calliditas Therapeutics Ab share price today?

Calliditas Therapeutics Ab share price today is as on at the close of the market. Calliditas Therapeutics Ab share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Calliditas Therapeutics Ab share?

Calliditas Therapeutics Ab share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Calliditas Therapeutics Ab stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Calliditas Therapeutics Ab Stock (CALT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Calliditas Therapeutics Ab on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Calliditas Therapeutics Ab Shares .

What is the minimum amount required to buy Calliditas Therapeutics Ab Stock (CALT) from India?

Indian investors can start investing in Calliditas Therapeutics Ab (CALT) shares with as little as ₹87.521 or $1 (as of August 24, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Calliditas Therapeutics Ab stock (as per the Rupee-Dollar exchange rate as on August 24, 2025). Learn more about fractional shares .

What are the returns that Calliditas Therapeutics Ab has given to Indian investors in the last 5 years?

Calliditas Therapeutics Ab stock has given 0.0% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?